Profusa (PFSA) Competitors

$0.45 +0.02 (+3.66%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$0.44 0.00 (-0.94%)

As of 05/15/2026 07:09 PM Eastern

PFSA vs. TNON, PAVM, XAIR, NXL, and BTCY

Should you buy Profusa stock or one of its competitors? MarketBeat compares Profusa with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profusa include Tenon Medical (TNON), PAVmed (PAVM), Beyond Air (XAIR), Nexalin Technology (NXL), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.

How does Profusa compare to Tenon Medical?

Profusa (NASDAQ:PFSA) and Tenon Medical (NASDAQ:TNON) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Tenon Medical has higher revenue and earnings than Profusa. Tenon Medical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	19.63	-$35.82M	-$167.67	N/A
Tenon Medical	$3.94M	2.02	-$12.56M	-$1.29	N/A

Profusa has a net margin of 0.00% compared to Tenon Medical's net margin of -270.09%. Profusa's return on equity of 0.00% beat Tenon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,196.99%
Tenon Medical	-270.09%	-560.04%	-115.53%

In the previous week, Tenon Medical had 2 more articles in the media than Profusa. MarketBeat recorded 7 mentions for Tenon Medical and 5 mentions for Profusa. Profusa's average media sentiment score of 0.39 beat Tenon Medical's score of -0.04 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenon Medical	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Profusa has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

9.8% of Profusa shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 11.4% of Profusa shares are held by insiders. Comparatively, 0.3% of Tenon Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Tenon Medical beats Profusa on 9 of the 15 factors compared between the two stocks.

How does Profusa compare to PAVmed?

Profusa (NASDAQ:PFSA) and PAVmed (NASDAQ:PAVM) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

In the previous week, PAVmed had 4 more articles in the media than Profusa. MarketBeat recorded 9 mentions for PAVmed and 5 mentions for Profusa. PAVmed's average media sentiment score of 0.50 beat Profusa's score of 0.39 indicating that PAVmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PAVmed has a consensus target price of $65.00, suggesting a potential upside of 895.41%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.8% of Profusa shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 11.4% of Profusa shares are held by insiders. Comparatively, 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PAVmed has lower revenue, but higher earnings than Profusa. PAVmed is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	19.63	-$35.82M	-$167.67	N/A
PAVmed	$70K	93.29	$400K	-$22.77	N/A

PAVmed has a net margin of 564.79% compared to Profusa's net margin of 0.00%. Profusa's return on equity of 0.00% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,196.99%
PAVmed	564.79%	-242.99%	-17.25%

Profusa has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

PAVmed beats Profusa on 13 of the 16 factors compared between the two stocks.

How does Profusa compare to Beyond Air?

Beyond Air (NASDAQ:XAIR) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

In the previous week, Profusa had 3 more articles in the media than Beyond Air. MarketBeat recorded 5 mentions for Profusa and 2 mentions for Beyond Air. Beyond Air's average media sentiment score of 0.44 beat Profusa's score of 0.39 indicating that Beyond Air is being referred to more favorably in the media.

Company	Overall Sentiment
Beyond Air	Neutral
Profusa	Neutral

Beyond Air currently has a consensus target price of $10.00, suggesting a potential upside of 1,908.44%. Given Beyond Air's stronger consensus rating and higher probable upside, analysts plainly believe Beyond Air is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 10.0% of Beyond Air shares are held by insiders. Comparatively, 11.4% of Profusa shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profusa has lower revenue, but higher earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$3.70M	1.77	-$46.62M	-$5.43	N/A
Profusa	$100K	19.63	-$35.82M	-$167.67	N/A

Profusa has a net margin of 0.00% compared to Beyond Air's net margin of -447.75%. Profusa's return on equity of 0.00% beat Beyond Air's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beyond Air	-447.75%	-268.82%	-98.49%
Profusa	N/A	N/A	-1,196.99%

Beyond Air has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Profusa has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Summary

Beyond Air and Profusa tied by winning 8 of the 16 factors compared between the two stocks.

How does Profusa compare to Nexalin Technology?

Profusa (NASDAQ:PFSA) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Profusa has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.56, indicating that its share price is 256% more volatile than the broader market.

Nexalin Technology has higher revenue and earnings than Profusa. Nexalin Technology is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	19.63	-$35.82M	-$167.67	N/A
Nexalin Technology	$275.58K	25.58	-$8.22M	-$0.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.8% of Profusa shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profusa has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Profusa's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,196.99%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

In the previous week, Profusa had 4 more articles in the media than Nexalin Technology. MarketBeat recorded 5 mentions for Profusa and 1 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 1.89 beat Profusa's score of 0.39 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Profusa	Neutral
Nexalin Technology	Very Positive

Summary

Nexalin Technology beats Profusa on 8 of the 13 factors compared between the two stocks.

How does Profusa compare to Biotricity?

Profusa (NASDAQ:PFSA) and Biotricity (NASDAQ:BTCY) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Profusa has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Biotricity has higher revenue and earnings than Profusa. Biotricity is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	19.63	-$35.82M	-$167.67	N/A
Biotricity	$12.06M	0.44	-$14.09M	-$0.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

9.8% of Profusa shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profusa has a net margin of 0.00% compared to Biotricity's net margin of -80.42%.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,196.99%
Biotricity	-80.42%	N/A	-188.47%

In the previous week, Profusa had 4 more articles in the media than Biotricity. MarketBeat recorded 5 mentions for Profusa and 1 mentions for Biotricity. Profusa's average media sentiment score of 0.39 beat Biotricity's score of 0.00 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biotricity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Profusa beats Biotricity on 8 of the 13 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.89M	$3.36B	$4.74B	$12.48B
Dividend Yield	N/A	N/A	5.93%	5.25%
P/E Ratio	0.00	3.23	22.92	25.24
Price / Sales	19.63	29.71	121.17	82.47
Price / Cash	N/A	4.29	50.14	56.04
Price / Book	-0.02	3.66	38.26	6.90
Net Income	-$35.82M	-$76.79M	$113.55M	$334.66M
7 Day Performance	-13.69%	2.75%	2.46%	0.13%
1 Month Performance	-31.17%	2.15%	4.53%	1.11%
1 Year Performance	N/A	93.35%	16.78%	30.62%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	0.1968 of 5 stars	$0.45 +3.7%	N/A	N/A	$1.89M	$100K	N/A	2	News Coverage Earnings Report
TNON Tenon Medical	0.7908 of 5 stars	$0.75 +0.7%	N/A	-35.7%	$8.37M	$3.94M	N/A	8	News Coverage Earnings Report Analyst Forecast
PAVM PAVmed	2.3245 of 5 stars	$7.01 -12.9%	$65.00 +827.2%	-65.4%	$8.02M	$70K	N/A	90	News Coverage
XAIR Beyond Air	2.6377 of 5 stars	$0.57 -2.6%	$10.00 +1,669.9%	-86.1%	$7.65M	$3.70M	N/A	70	Short Interest Increase
NXL Nexalin Technology	0.7 of 5 stars	$0.35 -3.3%	N/A	-72.4%	$7.41M	$301.65K	N/A	3	Positive News Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors

PFSA vs. TNON, PAVM, XAIR, NXL, and BTCY

How does Profusa compare to Tenon Medical?

Summary

How does Profusa compare to PAVmed?

Summary

How does Profusa compare to Beyond Air?

Summary

How does Profusa compare to Nexalin Technology?

Summary

How does Profusa compare to Biotricity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profusa (PFSA) Competitors

PFSA vs. TNON, PAVM, XAIR, NXL, and BTCY

How does Profusa compare to Tenon Medical?

Which has better earnings & valuation, PFSA or TNON?

Is PFSA or TNON more profitable?

Does the media refer more to PFSA or TNON?

Do analysts recommend PFSA or TNON?

Which has more risk and volatility, PFSA or TNON?

Do insiders & institutionals hold more shares of PFSA or TNON?

Summary

How does Profusa compare to PAVmed?

Does the media refer more to PFSA or PAVM?

Do analysts recommend PFSA or PAVM?

Do insiders & institutionals hold more shares of PFSA or PAVM?

Which has better earnings & valuation, PFSA or PAVM?

Is PFSA or PAVM more profitable?

Which has more risk and volatility, PFSA or PAVM?

Summary

How does Profusa compare to Beyond Air?

Does the media refer more to XAIR or PFSA?

Do analysts prefer XAIR or PFSA?

Do institutionals & insiders believe in XAIR or PFSA?

Which has stronger earnings and valuation, XAIR or PFSA?

Is XAIR or PFSA more profitable?

Which has more volatility & risk, XAIR or PFSA?

Summary

How does Profusa compare to Nexalin Technology?

Which has more volatility & risk, PFSA or NXL?

Which has preferable earnings and valuation, PFSA or NXL?

Do analysts rate PFSA or NXL?

Do insiders and institutionals believe in PFSA or NXL?

Is PFSA or NXL more profitable?

Does the media prefer PFSA or NXL?

Summary

How does Profusa compare to Biotricity?

Which has more volatility & risk, PFSA or BTCY?

Which has preferable earnings and valuation, PFSA or BTCY?

Do analysts rate PFSA or BTCY?

Do insiders and institutionals believe in PFSA or BTCY?

Is PFSA or BTCY more profitable?

Does the media prefer PFSA or BTCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools